88 Business View Magazine - May 2016
Much of Siegfried’s more recent, vast growth is a di-
rect result of the aforesaid company strategy known
as “Transform.” The Transform strategy was an initia-
tive put in place in 2010 by Siegfried’s CEO, Dr. Rudolf
Hanko, who was supported by Siegfried shareholders
to put in place a financial basis to support “Trans-
form” with an increase in share capital. Dr. Hanko’s
aim with “Transform” was to combine the firm’s once,
two separate divisions – drug product and drug sub-
stance - into one, while leveraging Siegfried’s inherited
knowledge and extensive experience, to complete all
the necessary elements that would position Siegfried
as a leading CMO and preferred partner supporting
the entire product life cycle for customers in both the
chemical and pharmaceutical industries. (Drug sub-
stances by definition are the chemical syntheses of
an active pharmaceutical ingredient, or API which are
then formulated into a drug for treatment of humans;
drug product is the finished formulation - the tablet,
capsule, injection, etc., for safe treatment of humans).
In order to strengthen its presence in both aforesaid
markets and to be recognized as a leading, complete
A Global Network
of Competencies
Zofingen
Switzerland
Drug Substance / Drug Product
Hameln
Germany
Drug Product
Saint-Vulbas
France
Drug Substance
Evionnaz
Switzerland
Drug Substance
Pennsville
USA
Drug Substance
Irvine
USA
Drug Product
Hal Far
Malta
Drug Product
Minden
Germany
Drug Substance
Nantong
China
Drug Substance
